cannabisnews.com: WSJ Reports on Development of CT-3 WSJ Reports on Development of CT-3 Posted by FoM on March 01, 2001 at 07:53:37 PT CT-3 Show Promise As Nonpsychoactive Pain Reliever Source: PRNewswire The Wall Street Journal reported today on the ongoing clinical development of Atlantic Technology Ventures, Inc.'s novel analgesic and anti-inflammatory drug CT-3 a synthetic derivative of tetrahydrocannabinol (THC), the active ingredient in marijuana. Atlantic's ongoing development of CT-3 as a nonpsychoactive cannabanoid was prominently featured in a front page article on efforts to develop THC-based drugs. This article also reported on research and development efforts by other individual scientists, academic labs and small drug companies that utilize various extractions of, or delivery mechanisms for naturally occurring THC, as opposed to its synthetic derivative. However, the article noted that big drug companies have traditionally been leery of the cost and political problems associated with marketing marijuana as a medicine, and that because cannabis is a natural product in the public domain, it cannot be patented. Despite these drawbacks, the article stated that "big companies," such as Pfizer, GlaxoSmithKline and Novartis, "are starting to get interested in the field." "Based on our recent experience, Atlantic is not surprised at this reported increased interest in THC-based drugs," according to Frederic P. Zotos, President of Atlantic. "CT-3 was designed to maximize the medical properties of marijuana without producing undesirable psychoactive properties. As a result, it does not suffer from political problems associated with marketing marijuana as a medicine, and enjoys strong worldwide patent protection well into the next decade," Mr. Zotos said. In light of CT-3's advantages over naturally occurring THC derivatives, Atlantic has been approached by several large pharmaceutical companies interested in potentially licensing CT-3 for a number of indications such as analgesia, anti-inflammatory disorders, glaucoma, neuropathic pain and cancer. Accordingly, "we have been sending quantities of CT-3 to these potential licensees for testing in their animal models," said Mr. Zotos. Atlantic successfully completed Phase I studies last year, clinically proving that CT-3 was very safe and that it would not cause typical marijuana-like effects in humans. "After we received the report of our Phase I studies," Mr. Zotos explained that, "we increased our efforts to sublicense CT-3 to suitable strategic partners to assist in clinical development, regulatory approval filing, manufacturing and marketing of CT-3." Atlantic is developing CT-3 as an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs). Preliminary cellular and animal studies have shown that CT-3 demonstrates analgesic and anti-inflammatory properties at microgram doses without central nervous system or gastrointestinal side effects. This makes the compound an attractive development candidate as an analgesic and anti-inflammatory agent with the potential to overcome the major side effects of current anti-inflammatory drugs. The use of cannabinoids for the treatment of a variety of diseases has aroused widespread medical and scientific interest, and has provided additional potential indications for CT-3. A limited number of clinical trials and the results of other animal or in vitro experiments published in scientific literature have shown the potential for cannabinoids to treat diseases such as, anxiety, psychosis, asthma, epilepsy, glaucoma, inflammation and swelling, movement disorders, spasticity and other neuromuscular disorders, pain and ulcers. Atlantic Technology Ventures, Inc. is a publicly held venture capital company specializing in investing in early-stage, breakthrough technologies and rapidly incubating these through a definitive proof-of-principle. Atlantic currently has four technology investments: Catarex, a device for cataract removal; CT-3, a synthetic derivative of marijuana for treating pain and inflammation; HTS Fiber Optic Transceiver; and 2-5A Antisense Enhancing Technology. Safe Harbor Statement: Cautionary statement under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: This press release contains certain forward-looking statements that relate to future scientific, business and financial performance. These statements are only predictions and are subject to a number of risks and uncertainties that may cause the actual events or results to differ from those discussed or implied in these statements. These risks and uncertainties include competition from other manufacturers of related technologies, the unavailability of any necessary intellectual property rights possessed by third parties, and certain of those risks described in Atlantic's most recent report on Form 10-KSB with the Securities and Exchange Commission. Source: Atlantic Technology Ventures, Inc. Contact: Vito A. Turso of Dan Klores Communications, 212-981-5156, for Atlantic Technology Ventures, Inc. Complete Title: Wall Street Journal Reports on Development of Atlantic Technology Ventures' CT-3 Synthetic Derivative of Marijuana Note: Atlantic Technology Ventures' CT-3 Shows Promise As Nonpsychoactive Pain Reliever Source: PRNewswirePublished: Wednesday, February 28, 2001 Copyright: 2001 PRNewswireWebsite: http://www.prnewswire.com/Related Articles: Smoking Gun - Praxis M.D.http://cannabisnews.com/news/thread8838.shtmlResearchers Aim To Develop Marijuana Without Highhttp://cannabisnews.com/news/thread8835.shtml Home Comment Email Register Recent Comments Help Comment #4 posted by FoM on March 01, 2001 at 22:46:18 PT Hi Rev. Jonathan Hi Rev. Jonathan Adler,Good to see you. Hope the weather is good down there in Hawaii! I'm quite sure it is. Have a good time in paradise! [ Post Comment ] Comment #3 posted by Rev. Jonathan Adler on March 01, 2001 at 22:30:56 PT: Pharma-toxical drugs! Aloha; Pause for a puff of the world's finest medijuana......now let me speak on this. Drugs and pharma-toxicals of all sorts claim to be cure-alls, but warn of toxic side effects. I call them pharma-toxicals. Drug companies look at cannabis and say... how can we profit? They think taking the high out will make it ok! How nonsensical. No toxicity is a hard one for FDA to stomache, but I prefer my "volcanic organic medijuana. Pause for another..... Yes it's the real stuff. Chronic clinical cannabis.... I am still waiting for Dr. Russo's first requisition. High! Ethan! Mahalos! Tonight they are recalling Proventyl, a medical inhaler because asthmatics were not getting medication during attacks when the inhaler failed. The Doctor's interviewed for the news tonight said, An episode of asthmatic distress could quickly lead to death, yet my application to Hawaii Dept. of Public Safety for mdical permit to use and grow cannabis for my asthma was rejected out of hand by Keuth Kamita and deferred to Dept. of Health for administrative approval of my doctor's request. I am still not approved by a bunk system that really doesn't apply to me. Stil planting seeds, growing weeds and meeting needs.... Bye from Paradise; Rev. Jonathan Adler/ Hawaii Medical Marijuana Hawaii Medical Marijuana Institute [ Post Comment ] Comment #2 posted by ras james rsifwh on March 01, 2001 at 11:11:09 PT SYMBIOTIC EVOLUTIONARY RELATIONSHIP How long have human beings been using Cannabis Sativa.The facts: 1. The cannabis fruits are highest in essential fatty acids needed for human development. 2. The cannabis fruits are second in protiens needed for human growth. 3. The cerebral cortex of the human mind has perfectly fitting receptor sites for natural cannabis THC. 4. A woman's placenta has THC recptors that help in the birth process.my "scientific guess" is that humans have been gathering the cannabis sativa flower heads; eating the seeds; and then throwing the flower heads into our fires for about 250,000 years. Yes people we are not homo sapien sapiens.We are in fact "Homo Cannabinoid Sapiens".Given the FACTS what is your best scientific guess? [ Post Comment ] Comment #1 posted by Ethan Russo, MD on March 01, 2001 at 08:49:43 PT: Pay Attention, Boys and Girls This drug, CT-3, AKA ajulemic acid, along with HU211 (dexanabinol) portend to be the two most likely candidates for subsequent licensure by the FDA.CT-3 is an analogue of delta-8-THC, and is non-psychoactive, but retains analgesic and anti-inflammatory effects. If it works as well as expected, it could have a large potential market.Dexanabinol is a non-psychoactive THC analogue that has proven very powerful as a glutamine receptor antagonist. Results to date in treatment of head injury, stroke and nerve gas (Sarin) exposure are very encouraging. It is an injected drug. It may prove to have application to other painful conditions.Both of these agents are apt to be extremely expensive once released. No new drug in the USA is economical. One will ask whether there is any pharmacological advantage of these agents with respect to THC itself, or especially clinical cannabis. That remains to be seen. The USA government surely sees these drugs as THE avenue to follow, and a hoped-for solution to the messy medical marijuana madness. [ Post Comment ] Post Comment Name: Optional Password: E-Mail: Subject: Comment: [Please refrain from using profanity in your message] Link URL: Link Title: